HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jeffery Auletta, MD
NMDP
Study Chair - Steven Devine, MD
NMDP
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
32 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Arizona
Phoenix, Arizona, United States
- Honor Health
Scottsdale, Arizona, United States
- University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
- City of Hope
Duarte, California, United States
- University of California San Francisco
San Francisco, California, United States
- Stanford University
Stanford, California, United States
- Colorado Blood Cancer Institute at Presbyterian St. Luke'S
Denver, Colorado, United States
- Mayo Clinic Jacksonville
Jacksonville, Florida, United States
- University of Miami Sylvester Cancer Center
Miami, Florida, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Emory University
Atlanta, Georgia, United States
- Greenbaum Cancer Center University of Maryland
Baltimore, Maryland, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Tufts University
Boston, Massachusetts, United States
- Karmanos Cancer Institute
Detroit, Michigan, United States
- University of Minnesota
Minneapolis, Minnesota, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Barnes Jewish Hospital / Washington University
St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center - Adults
New York, New York, United States
- University of North Carolina
Chapel Hill, North Carolina, United States
- Ohio State Medical Center
Columbus, Ohio, United States
- Oregon Health & Science University
Portland, Oregon, United States
- the Center for Bone Marrow Transplantation at Geisinger
Danville, Pennsylvania, United States
- Abramson Cancer Center
Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
- Tristar Centennial
Nashville, Tennessee, United States
- St. David'S South Austin Medical Center
Austin, Texas, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Methodist Hospital San Antonio
San Antonio, Texas, United States
- University of Virginia Health System
Charlottesville, Virginia, United States
- Fred Hutchinson Cancer Center
Seattle, Washington, United States
- Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 Dec 2023
- Primary completion
- 1 Feb 2026
- Completion
- 30 Jun 2026
- Last update posted
- 5 Feb 2026
- Registered enrollment
- 313
- Registry id
- NCT06001385
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.